Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
39.07
+0.22 (0.57%)
At close: Mar 6, 2026, 4:00 PM EST
39.50
+0.43 (1.10%)
After-hours: Mar 6, 2026, 7:24 PM EST

Vera Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Selling, General & Admin
100.224123.7921.9111.92
Upgrade
Research & Development
215.26126.1778.2368.9922.48
Upgrade
Operating Expenses
315.47167.17102.0190.934.4
Upgrade
Operating Income
-315.47-167.17-102.01-90.9-34.4
Upgrade
Interest Expense
-7.53-7.63-3.79-0.99-0.02
Upgrade
Interest & Investment Income
24.4820.717.981.750.02
Upgrade
Other Non Operating Income (Expenses)
-0.091.941.831.9-
Upgrade
EBT Excluding Unusual Items
-298.61-152.15-95.99-88.25-34.41
Upgrade
Gain (Loss) on Sale of Investments
----0.81-0.89
Upgrade
Gain (Loss) on Sale of Assets
----2.69
Upgrade
Other Unusual Items
-1----
Upgrade
Pretax Income
-299.61-152.15-95.99-89.06-32.61
Upgrade
Income Tax Expense
00000
Upgrade
Net Income
-299.62-152.15-95.99-89.06-32.61
Upgrade
Net Income to Common
-299.62-152.15-95.99-89.06-32.61
Upgrade
Shares Outstanding (Basic)
6455432713
Upgrade
Shares Outstanding (Diluted)
6455432713
Upgrade
Shares Change (YoY)
16.10%29.55%60.73%97.76%4099.14%
Upgrade
EPS (Basic)
-4.66-2.75-2.25-3.35-2.43
Upgrade
EPS (Diluted)
-4.66-2.75-2.25-3.35-2.43
Upgrade
Free Cash Flow
-241.73-135.65-92.24-67.66-23.71
Upgrade
Free Cash Flow Per Share
-3.76-2.45-2.16-2.55-1.76
Upgrade
EBITDA
-315.01-167.07-101.99-90.73-34.23
Upgrade
D&A For EBITDA
0.470.110.020.180.18
Upgrade
EBIT
-315.47-167.17-102.01-90.9-34.4
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.